Following an appeal, the NHS North East Treatment Advisory Group (NETAG) has issued a final recommendation and associated treatment protocol on the use of tolvaptan (Samsca®) for the syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The Group does not recommend its use following consideration of a treatment protocol for long term treatment. The group concluded that tolvaptan is unlikely to be cost-effective compared with existing treatment options and was concerned about the potential for unrestricted long-term treatment.

However, it is recognised that long-term treatment could be appropriate in certain circumstances according to a local protocol. Such cases must be referred via local individual funding request mechanisms.